Page 24 - Children Aged News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Read the latest BioNTech headlines - updated 24/7/365. We link to the best sources from around the world. Get the latest on BioNTech...

Vaccination. (Photo credits: Flickr) United Nations, July 17: India recorded the greatest increase in the world in the number of children not receiving a first dose of diphtheria-tetanus-pertussis combined vaccine in 2020, the UN has said, noting with concern that 23 million children globally missed out on basic vaccines through routine immunisation services last year due to disruptions caused by COVID-19. Data from the World Health Organisation (WHO) and the UN children's agency UNICEF showed that 23 million children missed out on basic childhood vaccines through routine health services in 2...

Patients outside AIIMS in Delhi File image | (Photo Credits: ANI) New Delhi, June 4: The All India Institute of Medical Sciences (AIIMS) Delhi's first study on breakthrough infections during the April-May period confirmed that none of the vaccinated people died due to the COVID-19 disease. COVID-19 diseaseBreakthrough infection denotes whether one has contracted Covid-19 after being fully vaccinated. According to the study, in the present group of vaccine breakthrough infections investigated using genome sequencing, closely overlapping and mirroring the COVID-19 cases in the state of Delhi, t...

A recent study reveals that Pfizer's vaccine against COVID-19 is less effective against coronavirus, but it gives protection against more variants of the virus first found in India. The study was conducted by France's Pasteur Institute. The study collected samples from 28 healthcare workers in the city of Orleans. �� COVID-19 Vaccine Update: Pfizer's Coronavirus Vaccine Less Effective But Still Gives Protection Against B.1.617 Variant, Reveals Study.

Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years as young as 6 years Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis Late-breaking Phase 2 data for rilzabrutinib, an investigational therapy for pemphigus vulgaris, a rare, debilitating autoimmune disease, to be presented at AAD PARIS - April 23, 2021 - New analyses from Dupixent (dupilumab) trials evaluat...